Publications by authors named "J Christopher Day"

Background: The idea of making science more accessible to nonscientists has prompted health researchers to involve patients and the public more actively in their research. This sometimes involves writing a plain language summary (PLS), a short summary intended to make research findings accessible to nonspecialists. However, whether PLSs satisfy the basic requirements of accessible language is unclear.

View Article and Find Full Text PDF

To determine the relationship between comorbid sleep-disordered breathing (SDB) and hospitalization rates related to diabetes mellitus (DM) and atherosclerotic disease (AD). This study used a retrospective cohort design from a large medical claims database with 5 years of data between 2018 and 2022. The presences of SDB, DM, and AD were identified using International Classification of Diseases (ICD-10) and relevant Current Procedural Terminology (CPT) codes.

View Article and Find Full Text PDF

Sarcoidosis is a multisystem granulomatous inflammatory disorder, of unknown aetiology, which causes a wide spectrum of clinical phenotypes. It can present at any age, most commonly between 20 and 60 years, with a roughly equal sex distribution. Diagnosis is often delayed due to multiple diagnostic mimics, particularly joint disease.

View Article and Find Full Text PDF

Physical materials from planetary bodies are crucial for understanding fundamental processes that constrain the evolution of the solar system, as samples can be analyzed at high precision and accuracy in Earth-based laboratories. Mars is the only planet outside of Earth from which we possess samples in the form of meteorites. Martian meteorites (n > 350) have enabled constraints to be placed on various aspects of the red planet's formation and evolution, notably: that Mars accreted and differentiated rapidly; that the planet has a complex volatile element evolution; and that it has always been volcanically active with a rich and diverse magmatic history.

View Article and Find Full Text PDF

Background: Vosoritide is a C-type natriuretic peptide analog that addresses an underlying pathway causing reduced bone growth in achondroplasia. Understanding the vosoritide treatment effect requires evaluation over an extended duration and comparison with outcomes in untreated children.

Methods: After completing ≥6 months of a baseline observational growth study and 52 weeks in a double-blind, placebo-controlled study (ClinicalTrials.

View Article and Find Full Text PDF